title: Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting.
abstract: The aim of this study was to assess the factors, including surgical portosystemic shunts, which affect survival in adults with Budd-Chiari syndrome. Multivariate retrospective analysis was performed using characteristics recorded at the time of diagnosis in 120 patients admitted from 1970 to 1992, of whom 82 were treated with surgical portosystemic shunts and 38 received only medical therapy. The 1-, 5-, and 10-year survival rates were 77 +/- 4%, 64 +/- 5%, and 57 +/- 6%, respectively. Survival was significantly better in the subgroup of patients diagnosed after versus before 1985. In both subgroups, and in patients with, as well as in patients without surgical shunts, 4 factors were found to be inversely and independently related to survival: age, response of ascites to diuretics, Pugh score, and serum creatinine. In patients diagnosed since 1985, an index combining these 4 factors allowed to differentiate patients with a good outcome (5-year survival 95%) from those with a poor outcome (5-year survival 62%; P <.05). There was no statistically significant and independent influence of surgical portosystemic shunts on survival. In conclusion, age, severity of liver failure, and presence of refractory ascites are the main prognostic factors in Budd-Chiari syndrome. Increased survival in recent years is consistent with improved management of hypercoagulable states as well as improved general care. It is uncertain whether surgical portosystemic shunting favorably modifies survival. Therefore, we recommend that surgical shunting should be restricted to management of refractory ascites or variceal bleeding in patients with otherwise good prognostic factors.
authors.affiliation: Service de chirurgie, Hôpital L. Mourier, Colombes, France.
authors.forename: G
authors.initials: G
authors.lastname: Zeitoun
authors.forename: S
authors.initials: S
authors.lastname: Escolano
authors.forename: A
authors.initials: A
authors.lastname: Hadengue
authors.forename: N
authors.initials: N
authors.lastname: Azar
authors.forename: M
authors.initials: M
authors.lastname: El Younsi
authors.forename: A
authors.initials: A
authors.lastname: Mallet
authors.forename: M J
authors.initials: MJ
authors.lastname: Boudet
authors.forename: J M
authors.initials: JM
authors.lastname: Hay
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: J P
authors.initials: JP
authors.lastname: Benhamou
authors.forename: J
authors.initials: J
authors.lastname: Belghiti
authors.forename: D
authors.initials: D
authors.lastname: Valla
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001201:Ascites; D001219:Aspartate Aminotransferases / Q000097:blood; D006502:Budd-Chiari Syndrome / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010976:Platelet Count; D011170:Portasystemic Shunt, Surgical; D016016:Proportional Hazards Models; D011517:Prothrombin Time; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase